SCIENTURE HOLDINGS INC
SCNXNASDAQTrading Snapshot
- Day Range
- $0.26 – $0.27
- 52-Week Range
- $0.24 – $2.60
- Volume
- $3.56B
- Avg Volume
- $3.87B
- Shares Outstanding
- 40.6M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $431,609
- Last Q Revenue
- $343,639
- P/E Ratio
- —
- P/S Ratio
- 11.0x
- EPS (TTM)
- $-0.35
- Dividend Yield
- 20.17%
- Dilution (1yr)
- +1653.9%
Why Investors Own SCNX
- ✓High-growth profile — revenue up +45.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCIENTURE HOLDINGS INC
SCNX
StockOtter · stockotter.spaceAbout SCIENTURE HOLDINGS INC
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narro
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U. S. naloxone market totals ~$144 million in annual sales and ~9. 8 mill